Naprelan and Zantac drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Naprelan (naproxen sodium) and Zantac (ranitidine hydrochloride). Common drug interactions include hepatic steatosis among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Naprelan and Zantac. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Naprelan?

Naprelan has active ingredients of naproxen sodium. eHealthMe is studying from 731 Naprelan users. Check the latest studies of Naprelan.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 434,161 Zantac users. Check the latest studies of Zantac.



On Jul, 07, 2026

22 people who take Naprelan and Zantac together, and have interactions are studied.

Naprelan and Zantac drug interactions.

What are the common drug interactions of Naprelan and Zantac, by gender? *:

female:

  1. Hepatic steatosis (fatty liver disease)
  2. Hip fracture
  3. Interstitial lung disease
  4. Intervertebral disc degeneration (spinal disc degeneration)
  5. Intervertebral disc protrusion (spinal disc protrusion)
  6. Joint range of motion decreased (disease of joint movement)
  7. Lymphadenopathy (disease or enlargement of lymph nodes)
  8. Metastases to bone (cancer spreads to bone)
  9. Neck pain
  10. Osteitis (a general term for inflammation of bone)

male:

  1. Chronic kidney disease
  2. Pain
  3. Anxiety
  4. Arteriosclerosis (thickening and hardening of arteries)
  5. Arthralgia (joint pain)
  6. Ataxia (loss of full control of bodily movements)
  7. Atelectasis (partial or complete collapse of the lung)
  8. Back pain
  9. Balanitis candida (inflammation of the glands penis by infection with candida albicans)
  10. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

What are the common drug interactions of Naprelan and Zantac, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Abdominal pain upper
  2. Cholecystitis chronic (long lasting infection of gallbladder)
  3. Decreased appetite
  4. Diarrhoea
  5. Nausea (feeling of having an urge to vomit)
  6. Ovarian cyst (fluid filled sac of the ovary)
  7. Swelling
  8. Weight decreased

20-29:

  1. Cholecystitis chronic (long lasting infection of gallbladder)
  2. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  3. Pain

30-39:

n/a

40-49:

  1. Gait disturbance
  2. Hepatic steatosis (fatty liver disease)
  3. Hip fracture
  4. Interstitial lung disease
  5. Intervertebral disc degeneration (spinal disc degeneration)
  6. Intervertebral disc protrusion (spinal disc protrusion)
  7. Joint range of motion decreased (disease of joint movement)
  8. Lymphadenopathy (disease or enlargement of lymph nodes)
  9. Metastases to bone (cancer spreads to bone)
  10. Neck pain

50-59:

  1. Insomnia (sleeplessness)
  2. Spinal column stenosis (narrowing of spinal column)
  3. Tooth disorder (tooth disease)
  4. Abdominal discomfort
  5. Actinomyces test positive
  6. Anaphylactic reaction (serious allergic reaction)
  7. Anxiety
  8. Arteriosclerosis (thickening and hardening of arteries)
  9. Arthralgia (joint pain)
  10. Ataxia (loss of full control of bodily movements)

60+:

  1. Chronic kidney disease
  2. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  3. Hyperchlorhydria (gastric acid levels are higher in stomach)
  4. Pulmonary embolism (blockage of the main artery of the lung)
  5. Rebound effect (take-back effect)
  6. Renal failure (kidney dysfunction)
  7. Renal haemangioma (kidney tumour filled with blood)
  8. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)

What are the existing conditions these people have? *

  1. Arthritis (form of joint disorder that involves inflammation of one or more joints): 10 people, 45.45%
  2. Metastases To Bone (cancer spreads to bone): 8 people, 36.36%
  3. Pain: 4 people, 18.18%
  4. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 13.64%
  5. Drowsiness: 3 people, 13.64%
  6. Hypersensitivity: 2 people, 9.09%
  7. High Blood Pressure: 2 people, 9.09%
  8. Gout (uric acid crystals building up in the body): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Naprelan and Zantac?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Naprelan and Zantac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Naprelan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zantac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Naprelan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zantac and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on naproxen sodium and ranitidine hydrochloride (the active ingredients of Naprelan and Zantac, respectively), and Naprelan and Zantac (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: